Home > Search Results: Vall d'Hebron Institut d'Oncologia
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.02 seconds.
Articles, 3 records found
Articles 3 records found  
1.
8 p, 712.6 KB Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study / Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Portnoy, D. C. (The West Clinic, Memphis, USA) ; Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ; Bodoky, G. (St László Hospital (Hongria)) ; Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ; Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ; Muro, K. (Aichi Cancer Center Hospital) ; Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ; Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ; Grothey, A. (Mayo Clinic, Phoenix, USA) ; O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ; Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ; Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ; Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131  
Detailed record - Creative Commons
2.
8 p, 518.2 KB Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) / Solis-Hernandez, Mª Pilar (Hospital Universitario Central de Asturias) ; Fernandez del Valle, Ana (Hospital Universitario Central de Asturias) ; Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Custodio, Ana (Hospital Universitario La Paz (Madrid)) ; Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ; Nuñez-Valdovino, Bárbara (Hospital Clinico Universidad de Chile (Santiago de Xile, Xile)) ; Sanchez Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia)) ; Matos, Ignacio (Hospital Universitari Vall d'Hebron) ; Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ; Lopez, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Viudez, Antonio (Complejo Hospitalario de Navarra) ; Izquierdo, Marta (Hospital Universitario Central de Asturias) ; Calvo-Temprano, David (Hospital Universitario Central de Asturias) ; Grande, Enrique (MD Anderson Cancer Center) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ; Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias) ; Universitat Autònoma de Barcelona ; Vall d'Hebron Institut d'Oncologia
The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. [...]
2019 - 10.1038/s41416-019-0558-7
British Journal of Cancer, Vol. 121 (september 2019) , p. 537-544  
Detailed record - Creative Commons
3.
9 p, 297.7 KB New clinical trial designs in the era of precision medicine / Garralda, Elena (Universitat Autònoma de Barcelona) ; Dienstmann, Rodrigo (Universitat Autònoma de Barcelona) ; Piris-Giménez, Alejandro (Universitat Autònoma de Barcelona) ; Braña, Irene (Universitat Autònoma de Barcelona) ; Rodon Ahnert, Jordi (Universitat Autònoma de Barcelona) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Universitat Autònoma de Barcelona ; Vall d'Hebron Institut d'Oncologia
Cancer treatment has made significant strides towards the promise of personalized medicine. Recent scientific advances have shown that there are numerous genetic deregulations that are common in multiple cancer types, raising the possibility of developing drugs targeting those deregulations irrespective of the tumour type. [...]
2019 - 10.1002/1878-0261.12465
Molecular Oncology, Vol. 13 (february 2019) , p. 549-557  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with